MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Boston Scientific Corporation Revenue 2011-2026 | BSX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.1 B | 16.7 B | 14.2 B | 12.7 B | 11.9 B | 9.91 B | 10.7 B | 9.82 B | 9.05 B | 8.39 B | 7.48 B | 7.38 B | 7.14 B | 7.25 B | 7.62 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.1 B | 7.14 B | 10.7 B |
Quarterly Revenue Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.06 B | 5.06 B | 4.66 B | 4.21 B | 4.12 B | 3.86 B | 3.53 B | 3.6 B | 3.39 B | - | 3.17 B | 3.24 B | 3.03 B | - | 2.93 B | 3.08 B | 2.75 B | - | 2.66 B | 2 B | 2.54 B | - | 2.71 B | 2.63 B | 2.49 B | - | 2.39 B | 2.49 B | 2.38 B | - | 2.22 B | 2.26 B | 2.16 B | - | 2.1 B | 2.13 B | 1.96 B | - | 1.89 B | 1.84 B | 1.77 B | - | 1.85 B | 1.87 B | 1.77 B | - | 1.74 B | 1.81 B | 1.76 B | - | 1.74 B | 1.83 B | 1.87 B | - | 1.87 B | 1.98 B | 1.92 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.06 B | 1.74 B | 2.63 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
574 K | $ 2.22 | 5.21 % | $ 3.47 M |  USA |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 10.45 | 0.29 % | $ 1.41 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.36 | -0.24 % | $ 600 M |  Israel |
 |
Alphatec Holdings
ATEC
|
764 M | $ 13.05 | 3.57 % | $ 1.96 B | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 4.27 | 9.21 % | $ 904 M | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.06 | 2.53 % | $ 151 M |  France |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
CONMED Corporation
CNMD
|
1.37 B | $ 37.34 | -0.16 % | $ 1.16 B | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.68 | 4.61 % | $ 37 M | USA |
 |
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
37 M | $ 11.16 | 1.18 % | $ 302 M | USA |
 |
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Establishment Labs Holdings
ESTA
|
211 M | $ 65.01 | 2.41 % | $ 1.93 B |  Costa-rica |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.45 | 0.16 % | $ 121 M | USA |
 |
InMode Ltd.
INMD
|
358 M | $ 13.65 | 1.64 % | $ 882 M | Israel |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
44.3 B | $ 110.71 | 0.69 % | $ 193 B | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 9.74 | -0.71 % | $ 349 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
1.3 M | $ 2.6 | 0.39 % | $ 153 M | Israel |
 |
Bio-Rad Laboratories
BIO
|
2.57 B | $ 269.48 | 3.15 % | $ 7.6 B | USA |
 |
Helius Medical Technologies
HSDT
|
644 K | $ 2.17 | -0.91 % | $ 1.32 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 32.75 | -0.27 % | $ 1.51 B | USA |
 |
Align Technology
ALGN
|
4 B | $ 176.12 | 3.94 % | $ 13.2 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.1 | 1.0 % | $ 701 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 33.74 | 2.99 % | $ 5.03 K | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
52.8 M | $ 3.74 | 1.91 % | $ 154 M | USA |
 |
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
459 M | $ 0.39 | -6.07 % | $ 40.1 M | USA |
 |
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.33 | - | $ 21.5 M | USA |
 |
IRadimed Corporation
IRMD
|
83.8 M | $ 102.8 | 1.09 % | $ 1.31 B | USA |